Results 131 to 140 of about 5,905,711 (364)

Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth

Frontiers in Oncology, 2017
The concept that cancer is a metabolic disease is now well acknowledged: many cancer cell types rely mostly on glucose and some amino acids, especially glutamine for energy supply.
Mariafrancesca Scalise, Lorena Pochini, Michele Galluccio, Lara Console, Cesare Indiveri, Cesare Indiveri   +5 more
doaj   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

NK-cells that identify glycopatterns and their anti-tumor potential against a background of epidemically significant viral infections

Analiz Riska Zdorovʹû, 2019
Risks related to tumors development against a background of viral infections as well as factors that determine such risks or reduce them have not been examined profoundly so far.
M.V. Lakhtin, V.М. Lakhtin, V.А. Aleshkin, S.S. Afanasiev   +3 more
doaj   +1 more source

CAR-T cell. the long and winding road to solid tumors [PDF]

, 2018
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment ...
A Heczey, AH Long, AM Leen, AP Cogdill, ARW Schröder, B Clémenceau, B Moldt, BD Koster, C Carpenito, C Zhang, CE Brown, CH June, CM Bollard, D Kobelt, DM Frey, DM Pardoll, DM Shayakhmetov, DW Lee, EI Buchbinder, EJ Lipson, EM Allen Van, F Bushman, F Ochi, F You, FS Hodi, G Gross, G Sconocchia, G Sconocchia, GL Beatty, H Karlsson, H Koehler, H Torikai, HC Ertl, HJ Pegram, I Caruana, J Badhiwala, J Ellis, J Wang, JE Bakema, JH Sampson, JL Tanyi, K Kono, K Kono, K Kudo, K Tamada, K Töpfer, KC Feng, L Bracci, L Zhang, LE Kandalaft, LM Rogers, LM Whilding, M Chmielewski, M Hegde, M Koneru, M Palma De, M Sadelain, M Sadelain, MA Ligtenberg, MC Milone, MCI Schalkwyk van, MD Stewart, ME Mikucki, ME Weijtens, MJ Besser, MJ Besser, MJ Butte, MJ Osborn, ML Davila, ML Davila, MM D’Aloia, MV Maus, N Ahmed, N Ahmed, O Walisko, P Kebriaei, PB Hackett, PC Schuberth, R Braster, R Monjezi, RA Morgan, RA Morgan, RJ Brentjens, RP Junghans, S Chabot, S Mohammed, S Nayak, S Sakaguchi, S Su, S Toyokuni, S Wilkie, SA Richman, SC Katz, SL Goff, SL Maude, SR Witting, SV Kulemzin, TR Medler, TR Simpson, V Arumugam, VD Fedorov, VD Sadelain, W Wang, XS Zhong, Z Eshhar, Z Grada, Z Wang   +106 more
core   +2 more sources

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Annals of Surgery, 2000
OBJECTIVE To analyze the outcome of 200 patients with gastrointestinal stromal tumor (GIST) who were treated at a single institution and followed up prospectively.
R. DeMatteo, J. Lewis, D. Leung, S. Mudan, J. Woodruff, M. Brennan   +5 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Interictal electroencephalographic findings in children and adults with temporal lobe tumors Eletrencefalograma interictal em crianças e adultos com tumores de lobo temporal

Arquivos de Neuro-Psiquiatria, 2006
OBJECTIVE: To characterize clinical and interictal electroencephalographic aspects of children and adults with temporal lobe epilepsy (TLE) due to tumoral lesions.
Renata C. Franzon, Maria Augusta Montenegro, Clarissa Lin Yasuda, Catarina A. Guimarães, Carlos A.M. Guerreiro, Fernando Cendes, Kette D. Valente, Marilisa M. Guerreiro   +7 more
doaj   +1 more source

Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: Genetic reclassification and correlation with clinical features [PDF]

, 2004
Background: Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant disorder predisposing to predominantly colorectal cancer (CRC) and endometrial cancer frequently due to germline mutations in DNA mismatch repair (MMR) genes, mainly ...
Baretton, G., Daum, J., Gross, M., Holinski-Feder, E., Kopp, R., Lohse, P., Muders, M., Mussack, T., Müller-Koch, Y., Schiemann, Uwe   +9 more
core   +1 more source

Cancer and nonextensive statistics [PDF]

, 2006
We propose a new model of cancer growth based on nonextensive entropy. The evolution equation depends on the nonextensive parameter q. The exponential, the logistic, and the Gompertz growth laws are particular cases of the generalized model. Experimental data of different tumors have been shown to correspond to all these tumor-growth laws.
arxiv   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source